BM
XBI icon

Baymount Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Baymount Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-360,000
Closed -$34.2M – 4
2024
Q1 		$34.2M Buy
+360,000
New +$33.4M 35.53% 2

Other funds holding XBI

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Baymount Management's XBI Position: Q2 2024 in Review

Baymount Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 360,000 shares — an estimated $34.2M sold.

Baymount Management first reported a position in XBI in Q1 2024 and held it in 1 quarter. The position peaked at $34.2M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • Baymount Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • Baymount Management sold 360,000 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $34.2M.
  • Baymount Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 1 quarter.
  • Baymount Management's State Street SPDR S&P Biotech ETF position peaked at $34.2M in Q1 2024.
  • 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Baymount Management's 13F filing for Q2 2024.